Immunohistochemical profile of breast cancer patients at a tertiary care hospital in South India

Asian Pacific Journal of Cancer Prevention

Volumn 12, Issue 3, 2011, Pages 625-629

  Ambroise, Moses ^a   Ghosh, Mitra ^a   Mallikarjuna, V S ^a   Kurian, Ann ^a  

^a APOLLO HOSPITALS   (India)

Author keywords

Breast cancer; Chennai; India; Receptor status

Indexed keywords

EID: 79958850449     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Almasri NM, Al Hamad M (2005). Immunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in breast carcinoma in Jordan. Breast Cancer Res,7,R598-604.
2. Aryandono T, Harijadi, Soeripto (2006). Hormone receptor status of operable breast cancers in Indonesia: correlation with other prognostic factors and survival. Asian Pac J Cancer Prev,7,321-4.
3. Ayadi L, Khabir A, Amouri H, et al (2008). Correlation of HER-2 over-expression with clinico-pathological parameters in Tunisian breast carcinoma. World J Surg Oncol,6,112.
4. Azizun-Nisa, Bhurgri Y, Raza F, Kayani N (2008). Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer. Asian Pac J Cancer Prev,9,553-6.
5. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V (2007). Descriptive analysis of Estrogen Receptor(ER)-Negative, Progesterone Receptor (PR)-Negative, and HER2-Negative Invasive Breast Cancer, the so-called Triple-Negative Phenotype. Cancer,109,1721-8.
6. Choi DH, Shin DB, Lee MH, et al (2003). A comparison of five immunohistochemical biomarkers and HER-2/neu gene amplification by fluorescence in situ hybridization in white and Korean patients with early-onset breast carcinoma. Cancer,98,1587-95.
7. Gluz O, Liedtke C, Gottschalk N, et al (2009). Triple-negative breast cancer-current status and future directions. Ann Oncol,20,1913-27.
8. Huang HJ, Neven P, Drijkoningen M, et al (2005). Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer. J Clin Pathol,58,611-6.
9. Iwase H, Kurebayashi J, Tsuda H,et al(2010). Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society. Breast Cancer, 17,118-24.
10. James R, Thriveni K, Ramaswamy G,et al (2008). Evaluation of immunohistochemistry and enzyme linked immunosorbent assay for her-2/neu expression in breast carcinoma. Ind J Clin Biochemistry, 23, 345-51.
11. Kamil M, Yusuf N, Khalid I, et al (2010).Association between HER-2/neu over-expression and clinico-pathologic parameters of breast cancer in northern Malaysia. Ceylon Med J,55,9-13.
12. Kumar V, Tewari M, Singh U, Shukla HS (2007). Significance of Her-2/neu protein over expression in Indian breast cancer patients. Indian J Surg,69,122-28.
13. Lal P, Tan LK, Chen B (2005). Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomas. Am J Clin Pathol,123,541-6.
14. Lund MJ, Butler EN, Bumpers HL, et al (2008).High prevalence of triple-negative tumors in an urban cancer center. Cancer,113,608-15.
15. Lund MJ, Trivers KF, Porter PL,et al (2009). Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Res Treat,113,357-70.
16. Munjal K, Ambaye A, Evans MF, et al (2009). Immunohistochemical analysis of ER, PR, Her2 and CK5/6 in Infiltrative Breast Carcinomas in Indian Patients. Asian Pac J Cancer Prev,10,773-8.
17. Moore MA, Ariyaratne Y, Badar F,et al(2010) Cancer epidemiology in South Asia - past, present and future. Asian Pac J Cancer Prev,11 Suppl 2,49-66.
18. Rhodes A, Jasani B, Balaton AJ, Barnes DM, Miller KD (2000). Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas: correlation with patient age, assay sensitivity, threshold value, and mammographic screening. J Clin Pathol,53,688-96.
19. Ravdin PM, Cronin KA, Howlader N, et al (2007). The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med,356,1670-4.
20. Saleh F, Abdeen S (2007). Pathobiological features of breast tumours in the State of Kuwait: a comprehensive analysis. J Carcinog,6,12.
21. Sandhu DS, Sandhu S, Karwasra RK, Marwah S (2010). Profile of breast cancer patients at a tertiary care hospital in north India. Indian J Cancer,47,16-22.
22. Saxena S, Rekhi B, Bansal A, et al (2005). Clinico-morphological patterns of breast cancer including family history in a New Dehi hospital, India- a cross-sectional study. World J Surg Oncol,3,67.
23. Shet T, Agrawal A, Nadkarni M, et al (2009). Hormone receptors over the last 8 years in a cancer referral center in India: what was and what is? Indian J Pathol Microbiol,52,171-4.
24. Stead LA, Lash TL, Sobieraj JE, et al (2009). Triple-negative breast cancers are increased in black women regardless of age or body mass index. Breast Cancer Res,11,R18.
25. Taucher S, Rudas M, Mader RM, et al (2003). Do we need HER-2/neu testing for all patients with primary breast carcinoma? Cancer,98,2547-53.
26. Tischkowitz M, Brunet JS, Bégin LR, et al (2007). Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer,7,134.
27. Takiar R, Srivastav A (2008). Time trend in breast and cervix cancer of women in India - (1990-2003). Asian Pac J Cancer Prev, 9, 777-80.
28. Vaidyanathan K, Kumar P, Reddy CO, et al(2010). ErbB-2 expression and its association with other biological parameters of breast cancer among Indian women. Indian J Cancer,47,8-15.
29. Vona-Davis L, Rose DP, Hazard H, et al (2008). Triple-negative breast cancer and obesity in a rural Appalachian population. Cancer Epidemiol Biomarkers Prev,17,3319-24.
30. Yeole BB (2008). Trends in cancer incidence in female breast, cervix uteri, corpus uteri, and ovary in India. Asian Pacific J Cancer Prev, 9, 119-22.